Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR2C | P28335 | 1/20 | 0.63 |
| ▸ | MAPK14 | Q16539 | 1/20 | 0.57 |
| ▸ | ROCK2 | O75116 | 2/20 | 0.54 |
| ▸ | ROCK1 | Q13464 | 1/20 | 0.54 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.53 |
| ▸ | TRPV1 | Q8NER1 | 1/20 | 0.52 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.52 |
| ▸ | NR1H4 | Q96RI1 | 1/20 | 0.52 |
| ▸ | DDR1 | Q08345 | 2/20 | 0.51 |
| ▸ | NAMPT | P43490 | 4/20 | 0.50 |
| ▸ | GPR139 | Q6DWJ6 | 1/20 | 0.49 |
| ▸ | KAT6A | Q92794 | 1/20 | 0.49 |
| ▸ | MMP13 | P45452 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17339262 | 0.85 | EPHX2 (0.70) | HTR2CMAPK14ROCK2ROCK1TRPV1 | |
| SCHEMBL17339606 | 0.84 | MMP13 (0.67) | TRPV1MMP13 | |
| SCHEMBL28844020 | 0.83 | HTR2C (0.62) | HTR2CMAPK14ROCK2ROCK1CHRM3 | |
| SCHEMBL17339576 | 0.81 | ALDH1A1 (0.66) | CHRM3TRPV1EPHX2NR1H4 | |
| SCHEMBL5607255 | 0.80 | HTR2C (0.61) | HTR2CMAPK14ROCK2ROCK1CHRM3 | |
| SCHEMBL5607247 | 0.80 | HTR2C (0.61) | HTR2CMAPK14ROCK2ROCK1CHRM3 | |
| SCHEMBL257930 | 0.80 | HPGD (0.63) | MAPK14CHRM3TRPV1MMP13 | |
| SCHEMBL2134167 | 0.78 | HTR2C (0.56) | HTR2CMAPK14ROCK2ROCK1CHRM3 | |
| SCHEMBL17339548 | 0.77 | CA1 (0.64) | CHRM3TRPV1EPHX2NR1H4 | |
| SCHEMBL17339269 | 0.77 | CA1 (0.64) | TRPV1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20190119281-A1 | Pyrazolopyrimidine Derivatives Useful as Inhibitors of Bruton's Tyrosine Kinase | LOXO ONCOLOGY INC (US) | 2019-04-25 | — | — | US | disclosed |
| EP-3154978-B1 | PYRAZOLOPYRIMIDINE DERIVATIVES USEFUL AS INHIBITORS OF BRUTON'S TYROSINE KINASE | LOXO ONCOLOGY INC (US) | 2019-04-03 | — | — | EP | disclosed |
| US-9975897-B2 | Pyrazolopyrimidine derivatives useful as inhibitors of Bruton's tyrosine kinase | LOXO ONCOLOGY, INC. (US) | 2018-05-22 | — | — | US | disclosed |
| US-20170129897-A1 | Pyrazolopyrimidine Derivatives Useful as Inhibitors of Bruton's Tyrosine Kinase | LOXO ONCOLOGY, INC. | 2017-05-11 | — | — | US | disclosed |
| EP-3154978-A1 | PYRAZOLOPYRIMIDINE DERIVATIVES USEFUL AS INHIBITORS OF BRUTON'S TYROSINE KINASE | Redx Pharma Plc (GB) | 2017-04-19 | — | — | EP | disclosed |
| WO-2015189620-A1 | PYRAZOLOPYRIMIDINE DERIVATIVES USEFUL AS INHIBITORS OF BRUTON'S TYROSINE KINASE | REDX PHARMA PLC (GB) | 2015-12-17 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190119281-A1 | Pyrazolopyrimidine Derivatives Useful as Inhibitors of Bruton's Tyrosine Kinase | BTK, SYK, LCK | HTR2C 3684/4885MAPK14 529/4885ROCK2 507/4885 |
| US-20170129897-A1 | Pyrazolopyrimidine Derivatives Useful as Inhibitors of Bruton's Tyrosine Kinase | BTK, SYK, LCK | HTR2C 3684/4885MAPK14 529/4885ROCK2 507/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.